Arlington Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$955K	Buy	1,827 +1,730	+1,784%	+$886K	0.07%	53
2026 Q2	$48.2K	Sell	97 -4	-4%	-$1.77K	﹤0.01%	273
2026 Q1	$45.1K	Buy	101 +89	+742%	+$41.5K	﹤0.01%	230
2025 Q4	$5.44K	Sell	12 -259	-96%	-$112K	﹤0.01%	373
2025 Q3	$106K	Sell	271 -36	-12%	-$15K	0.02%	256
2025 Q2	$137K	Buy	307 +3	+1%	+$1.38K	0.03%	222
2025 Q1	$147K	Buy	304 +12	+4%	+$5.59K	0.03%	208
2024 Q4	$118K	Hold	292	–	–	0.02%	246
2024 Q3	$136K	Hold	292	–	–	0.03%	217
2024 Q2	$137K	Buy	292 +233	+395%	+$101K	0.03%	205
2024 Q1	$24.7K	Sell	59 -8	-12%	-$3.38K	0.01%	320
2023 Q4	$27.3K	Buy	67 +33	+97%	+$12.2K	0.01%	327
2023 Q3	$11.8K	Buy	+34	New	+$11.9K	﹤0.01%	220

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Arlington Trust's VRTX Position: Q3 2026 in Review

Arlington Trust increased its Vertex Pharmaceuticals (VRTX) stake by 1,784% in Q3 2026, buying an estimated $886K and bringing the position to 1,827 shares worth $955K. The position accounts for 0.07% of the portfolio, ranked #53.

Arlington Trust first reported a position in VRTX in Q3 2023 and has held it in 13 quarters since. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Arlington Trust held 1,827 shares of Vertex Pharmaceuticals worth $955K as of Q3 2026.
Arlington Trust bought 1,730 Vertex Pharmaceuticals shares in Q3 2026, an estimated $886K.
Vertex Pharmaceuticals made up 0.07% of Arlington Trust's portfolio in Q3 2026, its #53 holding.
Arlington Trust first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Arlington Trust's 13F filing for Q3 2026, filed 20 Oct 2026.